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A B S T R A C T
Sleep and circadian rhythms are among the most powerful but least understood contributors to cognitive per-
formance and brain health. Here we capitalize on the circadian resetting effect of blue-wavelength light to phase
shift the sleep patterns of adult patients (aged 18–48 years) recovering from mild traumatic brain injury (mTBI),
with the aim of facilitating recovery of brain structure, connectivity, and cognitive performance. During a
randomized, double-blind, placebo-controlled trial of 32 adults with a recent mTBI, we compared 6-weeks of
daily 30-min pulses of blue light (peak λ = 469 nm) each morning versus amber placebo light (peak
λ = 578 nm) on neurocognitive and neuroimaging outcomes, including gray matter volume (GMV), resting-state
functional connectivity, directed connectivity using Granger causality, and white matter integrity using diffusion
tensor imaging (DTI). Relative to placebo, morning blue light led to phase-advanced sleep timing, reduced
daytime sleepiness, and improved executive functioning, and was associated with increased volume of the
posterior thalamus (i.e., pulvinar), greater thalamo-cortical functional connectivity, and increased axonal in-
tegrity of these pathways. These findings provide insight into the contributions of the circadian and sleep sys-
tems in brain repair and lay the groundwork for interventions targeting the retinohypothalamic system to fa-
cilitate injury recovery.
1. Introduction
Sleep and circadian rhythms have potent effects on human health,
neurobiology, and cognitive functioning. Without the benefit of re-
storative sleep, elementary cognitive performance declines rapidly and
is accompanied by unpredictable lapses of attention (Durmer and
Dinges, 2005), and impairments in higher-order cognitive capacities
such as judgment, decision-making, and executive functions (Killgore
et al., 2006; Killgore et al., 2007; Tucker et al., 2010). At the neural
level, sleep is critical for processes that facilitate physiological main-
tenance and repair, including flushing out accumulated neurotoxins
(Xie et al., 2013), restoration of damaged DNA in neurons (Bellesi et al.,
2016), production of oligodendrocyte precursor cells involved in
myelin formation (Bellesi et al., 2013), sustainment of myelin sheath
thickness (Bellesi et al., 2018), and maintaining the structural plasticity
and homeostasis of synaptic connections (de Vivo et al., 2017; Tononi
and Cirelli, 2014). Animal models demonstrate that sleep plays a vital
role in recovery from brain injury (Gao et al., 2010; Zunzunegui et al.,
2011), presumably through many of the mechanisms just described.
Clearly, one of the many functions of sleep is to facilitate repair and
restoration of brain systems that have been damaged, depleted, or de-
graded. Sleep, however, is not driven solely by homeostatic forces; our
propensity for sleep is inextricably linked with the diurnal circadian
rhythm of melatonin secretion by the pineal gland and the attendant
fluctuations in alertness. Because retinal light exposure suppresses
melatonin, circulating levels of this hormone are nearly absent
throughout the circadian day, but typically rise dramatically as light
levels decline in the evening (Cajochen et al., 2003). For humans, the
most efficient, restful, and restorative sleep occurs when the sleep cycle
is closely aligned with the circadian night (Arendt, 2006; Lavie, 2001).
Circadian rhythms are demonstrated by almost every cell within the
human body, comprising a hierarchical multi-oscillator system that is
regulated by the suprachiasmatic nucleus (SCN) of the hypothalamus
(Honma, 2018). The near 24-hour rhythm of this system is maintained
by a molecular entrainment process that resets the circadian clock each
period via retinal exposure to light. When light strikes the retina, it
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stimulates melanopsin-based intrinsically photosensitive retinal gang-
lion cells (ipRGCs) that are uniquely sensitive to wavelengths in the
blue range of the light spectrum (Panda et al., 2005; Provencio et al.,
2000; Qiu et al., 2005). These ipRGCs project extensively, via the re-
tinohypothalamic tract (RHT), to the SCN (Hattar et al., 2002; Panda
et al., 2002), which in turn, suppresses the production of melatonin by
the pineal gland (Sapede and Cau, 2013). Thus, exposure to blue wa-
velength light in the morning suppresses melatonin and phase advances
the circadian rhythm (i.e., sleep onset occurs earlier in the next period)
while similar exposure in the evening leads to a phase delay (i.e., sleep
onset will be pushed back later in the next period). This modifiability of
the circadian rhythm by light exposure has led to recent efforts to use
targeted phototherapy to treat circadian-related sleep problems.
While many types of sleep difficulties could potentially benefit from
light exposure interventions, one disorder where sleep may play a key
role in brain repair and recovery is mild traumatic brain injury (mTBI)
(Raikes and Killgore, 2018). Approximately 50% of patients with an
mTBI experience chronic sleep disruption and associated cognitive de-
crements following injury (Orff et al., 2009; Rao et al., 2008; Verma
et al., 2007). Critically, mTBI is associated with disturbances in the
normal rhythm of melatonin production (Grima et al., 2016; Shekleton
et al., 2010). As melatonin production in the evening plays a crucial
role in regulating sleep onset, disruptions in this cycle can have pro-
nounced effects on sleep quality (Grima et al., 2016; Shekleton et al.,
2010). Moreover, sleep problems following an mTBI are associated with
worse cognitive recovery and greater neuropsychiatric complications
(Gilbert et al., 2015; Sullivan et al., 2016). Based on the aforementioned
role of sleep in neural maintenance and repair, sleep disturbance in
mTBI may hinder normal brain recovery following an injury. We,
therefore, proposed to facilitate recovery from an mTBI by optimizing
the timing and quality of sleep via targeted light exposure, which has
not been directly assessed through experimental research. Sinclair and
colleagues first demonstrated that morning blue-wavelength light ex-
posure was effective at reducing subjective fatigue and daytime slee-
piness in patients recovering from TBI (Sinclair et al., 2014), however,
objective outcomes were not measured. More recently, our team re-
ported preliminary evidence that morning blue light exposure may be
helpful in changing the water diffusion patterns of cerebral white
matter in patients recovering from mTBI (Bajaj et al., 2017). However,
full examination of the combined effects of blue light treatment on
circadian timing, neurocognitive performance, and multimodal assess-
ment of neural mechanisms has not been undertaken.
Here, we identified the cognitive and neurobiological changes
produced by a 6-week intervention of daily morning blue-wavelength
light exposure in individuals recovering from a non-complicated mTBI.
In a randomized, double-blind, placebo-controlled trial, adults with a
documented mTBI in the preceding 18 months used an LED lightbox
each morning for 30-min. Each device was fitted with either BLUE or
AMBER LEDs (see Fig. 1). Sleep/wake activity was monitored with
wrist actigraphy and on-line sleep diaries for one week before treat-
ment, and throughout the 6-week intervention period. Participants also
completed a comprehensive neuropsychological assessment battery, a
series of objective multiple sleep latency tests (MSLTs), and functional
and structural magnetic resonance imaging (MRI) scans on the day
preceding the treatment period and immediately upon completion of
the intervention. We hypothesized that the blue light intervention
would lead to a greater phase advance in the circadian rhythm, im-
proved sleep, and enhanced daytime alertness relative to amber pla-
cebo. Further, we hypothesized that compared to the placebo condition,
the blue light would produce greater improvement in neurocognitive
performance and symptom reduction, which would correspond to in-
creased functional and structural connectivity within brain networks
involved in visual attention.
2. Methods
2.1. Participants
Individuals with a documented history of an mTBI in the preceding
18 months were recruited from the greater Boston Metropolitan area to
participate. Interested volunteers first underwent a rigorous telephone
screening interview, followed by a detailed in-person interview to de-
termine eligibility. Volunteers were between the ages of 18 and 50 and
had experienced a “concussion” or non-complicated mTBI within the
preceding 18 months, but no sooner than 4 weeks prior to their initial
assessment. Before participation, all individuals were required to pro-
vide written documentation by a medical or other relevant professional
(e.g., physician, nurse, emergency medical technician, coach, physical
trainer, police officer, security guard) who either witnessed or was in-
volved in the immediate response to the injury. Eligible volunteers were
required to meet the definition of an mTBI as specified by the VA/DoD
practice guidelines (VA/DoD Management of Concussion/mTBI
Working Group, 2009), which define an mTBI as a traumatically in-
duced structural injury and/or physiological disruption caused by an
external force (e.g., head impact, blast wave) leading to an alteration in
mental status (e.g., confusion, disorientation, retrograde or anterograde
amnesia), consciousness (i.e., loss of consciousness< 30 min; alteration
of consciousness up to 24 h), or post-traumatic amnesia up to 24 h, and/
or a Glasgow Coma Scale ≥13. For this study, all participants were also
required to have reported the onset of significant sleep-related pro-
blems that emerged or worsened following the injury. Only primary
English speakers (i.e., those who began speaking English as their pri-
mary language in the home by 3 years of age), and those who were
right-handed according to the Edinburgh Handedness Inventory
(Oldfield, 1971) were included. Potential volunteers were also excluded
for any history of neurological, mood, or psychotic disorder that was
present before the index traumatic injury, as well as abnormal visual
acuity not correctable by contact lenses, metal within the body, preg-
nancy, or other contraindications for MRI. Other exclusionary criteria
included current or anticipated shift work, intent to leave the time zone
during the course of the study, use of contraindicated medications (i.e.,
sleep medications; medications that affect neuroimaging), or use of il-
licit substances, including recent or long-term marijuana use, or ex-
cessive alcohol use (as defined by CDC criteria). Prior to enrollment, all
participants completed written informed consent, and were compen-
sated for their time in the study. The protocol for this experiment was
approved by the Institutional Review Boards (IRB) of Partners Health
Care, McLean Hospital, and the U.S. Army Human Use Protections Of-
fice.
Primary endpoints for this study, collected at baseline and post-
treatment, included 1) actigraphically measured sleep (minutes per
night), 2) actigraphically measured circadian phase shift (i.e., shift in
sleep onset time, wake time, and midpoint of the sleep period), and 3)
subjective sleepiness, and 4) objective sleepiness. Secondary endpoints
included 1) cognitive performance (i.e., psychomotor vigilance, neu-
ropsychological performance, and executive functioning), 2) brain vo-
lumetrics, 3) functional connectivity, and 4) white matter axonal in-
tegrity. Each of these was assessed at the baseline week or visit and
again during the final week or follow-up visit. A total of 38 participants
met full criteria for initial enrollment in the study. However, due to
participant non-compliance (n = 2), disqualifying psychopathology
(n = 1), and claustrophobia upon entering the scanner (n = 1), 34
participants were ultimately randomized to one of the treatment groups
(Fig. 2). Two participants in the BLUE condition failed to complete
required study procedures during the course of treatment, yielding
complete data for most outcome measures from 32 participants (15
male; 17 female) ranging in age from 18 to 48 years (M = 23.27;
SD = 7.14). Of these participants, n = 16 (50%) received the active
BLUE light condition and n = 16 (50%) received the placebo AMBER
placebo light condition. Table 1 presents the demographic data for the
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Fig. 1. Light therapy conditions and experimental design. (a) Participants received either a blue (active condition) or amber (placebo condition) light box fitted with
light-emitting diodes. (b) The participant was instructed to place the device at arm’'s length on a table at an approximately 45-degree angle and bathe their face with
the light for 30-minutesmin each morning. (c) The study lasted for 7-weeks. The figure shows that the participant wore an actigraph sleep monitor for the entire study
period. After one week of baseline actigraphy, the participant completed a full day of neurocognitive assessments, magnetic resonance imaging (MRI) scans, and
multiple sleep latency tests (MSLTs). Participants were then randomized to one of the two light treatment conditions (blue versus amber), during which time they
used the lightbox each morning. At the end of 6-weeks, participants returned to complete another day-long assesses session with the same measures collected at
baseline. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Participant flow diagram. The figure shows that 3 participants were randomly assigned to either the active blue light condition or placebo amber light
condition. Two participants from the blue group were excluded due to non-compliance, yielding 16 participants per group in the final analysis. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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samples.
2.2. General procedure
Over seven weeks, participants completed three laboratory visits,
including two full-day neurocognitive assessments plus neuroimaging
scans, and were randomly assigned to complete a 6-week at-home light
treatment regimen with either daily BLUE or AMBER light therapy each
morning.
2.2.1. Visit 1: Intake
Upon arrival, each eligible participant completed the informed
consent process followed by the Neurobehavioral Symptom Inventory
(NSI) (King et al., 2012), and the MINI International Neuropsycholo-
gical Interview (MINI) (Sheehan et al., 1998) to screen for psycho-
pathology. Each participant was then fitted with an actigraphic sleep
monitor wristwatch (Actiwatch Spectrum, Philips Respironics, OR,
USA) and shown how to log onto a secure web-based sleep diary to
complete daily questions about sleep and activity. Participants were
instructed to wear the actigraph watch continuously for the duration of
the study and return to the lab for a baseline neurocognitive assessment
and MRI scan in one week.
2.2.2. Visit 2: Baseline neurocognitive assessment/MRI scan
After one week of at-home baseline actigraphic sleep assessment,
participants returned for a baseline neurocognitive and neuroimaging
assessment. Participants arrived at the lab at 8:00 a.m. to complete pre-
scan procedures, including a pregnancy test for females and brief
practice tasks for the functional portion of the scan. Beginning at
9:00 a.m., participants underwent a 60-min neuroimaging scan that
included standard structural MRI (MPRAGE), resting-state functional
MRI, and diffusion tensor imaging (DTI). After leaving the scanner at
10:00 a.m., participants completed a half-hour neurocognitive assess-
ment with the Repeatable Battery of Neuropsychological Status
(RBANS). Between 10:30–11:00 a.m., polysomnographic electrodes
were applied, and the participant underwent the first of three trials of
the Multiple Sleep Latency Test (MSLT) at 11:50 a.m. After the MSLT, a
break for lunch occurred, followed by administration of a measure of
balance and stance stability at 1:15 p.m. A second MSLT occurred at
1:50 p.m. Multiple sleep and symptom questionnaires were adminis-
tered, followed by the Tower of London at 3:15 p.m., and a third MSLT
at 3:50 p.m. After testing, electrodes were removed and the participant
was provided with a light therapy device with a full demonstration on
its use, as well as a printed instruction brochure that provided detailed
information about the use of the device.
2.2.3. 6-week light therapy
Based on a pre-established computer-generated randomization
scheme, participants were provided either a BLUE or AMBER light
device (described in greater detail below) in a double-blind manner
(i.e., participants were not informed that there were different colours of
lights and all study staff with direct participant contact were blind to
the colour of light device assigned to each participant). Participants
were instructed to activate the light device every morning within two
hours of awakening, but no later than 11:00 a.m., and use the device
continuously for 30 min. When using the device, participants were in-
structed to place the lightbox at approximately arm's length (20–30 in.
distance from the face) at a slight angle (20–40°), so that the light
would bathe both sides of the face, and were encouraged to avoid
looking directly at the diodes to avoid visual discomfort. The device
was programmed to turn off automatically after 30 min of continuous
use. Additionally, participants were instructed to log onto a secure
website to complete a sleep and light use diary each morning after the
completion of light exposure.
2.2.4. Visit 3: Post-treatment neurocognitive assessment/MRI scan
Upon completion of the 6-weeks of daily morning light treatment,
participants returned to the lab for a final assessment session, which
was virtually identical to the baseline session (Visit 2). At the end of the
day, participants returned all equipment and were released from the
study.
2.3. Assessment measures
The following assessment measures and devices were used:
2.3.1. Personality and psychodiagnostic assessment
At Visit 1, a trained technician administered the Mini-International
Neuropsychiatric Interview (M.I.N.I.), a psychometrically validated
scale for assessing psychopathology (Sheehan et al., 1998), and the VA
National Traumatic Brain Injury Neurobehavioral Symptom Inventory
(NSI) (King et al., 2012). At Visit 2, participants completed several self-
report assessment scales including the Beck Depression Inventory (BDI-
II) (Beck et al., 1996), Rivermead Postconcussion Symptom Ques-
tionaire (RPCSQ) and basic questionnaires regarding sleep history, in-
jury history, caffeine use, and demographics.
2.3.2. Actigraphy
Participants wore an Actiwatch Spectrum (Philips Respironics)
wristwatch actigraph to monitor activity and sleep. The device col-
lected wrist activity movement counts and accumulated light exposure
every 60 s throughout the duration of the study. After each participant's
study run, the activity data were downloaded from the watch.
2.3.3. Sleepiness and subjective sleep need assessment
At each visit, participants completed the Epworth Sleepiness Scale
(ESS)(Johns, 1991), a measure of typical daytime sleepiness. Ad-
ditionally, at seven times during each visit day (8:55 a.m., 10:05 a.m.,
11:40 a.m., 1:05 p.m., 1:35 p.m., 2:35 p.m., 3:35 p.m.), participants
completed a rapid single-item 7-point Likert assessment of immediate
sleepiness with the Stanford Sleepiness Scale (SSS)(Herscovitch and
Broughton, 1981). Additionally, as an indicator of perceived sleep need,
we also asked participants to indicate “how many hours do you need to
sleep to feel your best.”
2.3.4. MSLT
Following the MRI procedure, each participant underwent a poly-
somnography (PSG) hook-up following standard procedures using the
10–20 system. A total of 14 leads were connected (i.e., A1, A2, O1, O2,
Cz, C3, C4, F3, F4, LEOG, REOG, P3, Pz, P4). At three times during the
assessment session (i.e., 11:50 a.m., 1:50 p.m., 3:50 p.m.), participants
were escorted to a private, infrared video-monitored, sleep chamber to
complete the multiple sleep latency test (MSLT). The participant laid
supine on a bed and was connected to a Nihon Kohden Polysmith
system (software version 11.0), with an amplifier (JE-912AK) and
Table 1
Baseline demographics for blue and amber groups.
Blue Amber Test p-value
N 16 (50%) 16 (50%)
Female 9 (56.2%) 8 (50%) χ2 (1) = 0.125 0.72
Male 7 (43.8%) 8 (50%)
Age 23.2 (7.1) 23.3 (7.4) t(30) = 0.037 0.97
Education 15.0 (2.4) 14.6 (2.2) t(30) = 0.466 0.65
# Concussions 2.4 (1.8) 2.2 (1.6) t(30) = 0.368 0.72
Months Since Injury 6.8 (4.4) 6.7 (3.6) t(30) = 0.066 0.95
RPCSQ Total 13.6 (11.1) 16.7 (8.3) t(30) = 0.883 0.38
NSI 18.4 (19.4) 16.9 (10.5) t(30) = 0.260 0.80
BDI 7.3 (6.6) 7.1 (3.4) t(30) = 0.134 0.89
FOSQ 16.1 (2.9) 16.5 (2.1) t(30) = 0.38 0.71
MEQ 51.8 (4.3) 50.8 (6.5) t(30) = 0.514 0.61
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remote headbox (JE-915A). After standard biocalibration, the partici-
pant was instructed to lie quietly and try to relax. The lights were then
turned off. PSG recording continued for 20 min and was monitored
continuously by a trained technician in real time. The procedure was
terminated after 20 min or was ended early if there were three con-
secutive 30-s epochs of sleep stage N1 or one continuous epoch of any
other sleep stage. Each recording was then independently scored by a
trained and certified polysomnographic technician to determine the
number of minutes of wakefulness before entering into stage N1 or
deeper sleep. A score of 20 indicated no sleep was measured.
2.3.5. Psychomotor vigilance test (PVT)
At three times during the course of each assessment session
(11:30 a.m., 1:25 p.m., 3:25 p.m.), participants completed a 10-min
assessment of attention and vigilance with the psychomotor vigilance
test (PVT) (Dinges and Powell, 1985) on a desktop computer. During
the task, participants were required to monitor a black screen and press
a response key as quickly as possible whenever a target stimulus ap-
peared in the center of the screen. Response time feedback was pro-
vided for each response. Each stimulus was presented in a pseudo-
random fashion with an inter-stimulus interval that ranged randomly
without replacement from 2 to 10 s.
2.3.6. Neurocognitive assessment
From approximately 10:05–10:35 a.m., participants completed the
RBANS, a brief battery of well-normed neuropsychological tests that is
commonly used for assessing individuals with traumatic brain injury.
The test provides several index scores, including: Immediate Memory,
Visuospatial/Constructional, Language, Attention, Delayed Memory,
and Total Score. Two alternate forms were counterbalanced across the
two groups for each administration. Additionally, at approximately
3:15 p.m., participants completed a 10-trial computerized version of the
TOL as a measure of executive functioning (i.e., planning and sequen-
cing ability) (Colorado Assessment Tests, http://www.catstests.com).
On each trial, the participant began with a starting “tower” that con-
sisted of three “pegs” of differing lengths, each with an arrangement of
three different coloured “beads” in various configurations upon the
pegs. To solve the puzzle, the examinee must rearrange the beads to
match a pre-specified goal pattern as quickly and in as few moves as
possible. Dependent variables from this task included the number of
moves required to match the goal arrangement, the average total move
time, and an index of throughput that accounted for both speed and
accuracy (i.e., [(proportion of correct moves)/(average total move time
in seconds)] x 0.60).
2.3.7. Light exposure devices
At the conclusion of Visit 2, participants were provided with either a
BLUE or AMBER a light therapy device to be used each morning. The
devices were manufactured by Philips Electronics (Stamford, CT). All
units were identical in design, with the exception of the colour wave-
length of the LEDs. Each device consisted of a 13.5 × 14 cm plastic
encased table-mounted device with a 10 × 6 array of light emitting
diodes (LEDs). Each LED was encased in a 1 × 1 cm cubical projection
element covered by a translucent plastic window. For the active BLUE
condition, participants were provided with a commercially available
Philips goLITE BLU® Energy Light device (Model HF3321/60). The
goLITE BLU Energy Light has a narrow bandwidth (peaking at
λ = 469 nm, at 214 Lux, and single panel irradiance (mW/cm2) = 0.11
at 80 cm). The AMBER placebo devices were provided on loan by the
manufacturer. The AMBER devices were essentially identical in design
to the goLITE BLU devices, with the exception that they were fitted with
amber LEDs (peaking at λ = 578 nm, at 188 Lux, and panel irradiance
(mW/cm2) = 0.04 at 80 cm). Participants were instructed to use the
device on its highest setting, and the device was set to deactivate after
30 min of continuous use.
2.4. Neuroimaging methods
Data were collected at baseline and post-treatment using a 3.0 T
magnetic resonance imaging scanner (Siemens Tim Trio, Erlangen,
Germany) using a 32-channel head coil. All scans occurred between
9:00–10:00 a.m.
2.4.1. Structural neuroimaging
Volumetric data were collected using a T1 weighted 3D magneti-
zation-prepared rapid acquisition gradient echo (MPRAGE) sequence
(TR/TE/flip angle = 2.1 s, 2.3 ms, 12°) that consisted of 176 sagittal
slices (256 × 256 matrix) with a slice thickness of 1 mm and a voxel
size of 1 × 1 × 1 mm3. T1 weighted structural images were pre-
processed using the Computational Anatomy Toolbox (CAT12) (http://
www.neuro.uni-jena.de/cat/) in SPM12 (http://www.fil.ion.ucl.ac.uk/
spm/software/spm12/). Images were realigned to the anterior-pos-
terior commissure axis and then segmented using the longitudinal pi-
peline into gray matter, white matter, and cerebrospinal fluid using
VBM12, a fully automated algorithm in SPM12. Segmented images
were used to create a custom DARTEL template and then the images
were normalized to Montreal Neurological Institute (MNI) space.
Smoothing of normalized images was performed with a 10 mm full
width at half maximum (FWHM) isotropic Gaussian kernel.
2.4.2. Functional neuroimaging
Resting-state functional MRI images were acquired for 6 min using a
gradient echo T2*-weighted sequence (TR/TE/flip angle = 2 s/30 ms/
90°) and a 224 mm FOV. The resting functional images were collected in
the same plane with 34 coronal slices and a voxel size of
3.5 × 3.5 × 3.5 mm3, in an interleaved excitation order, with foot-to-
head phase encoding. At the beginning of each scan, four images were
acquired and discarded to allow for T1-equilibrium effects. Head
movement was restricted using expandable foam cushions, and subjects
were asked to remain awake with eyes open while lying still during the
scans. Participants were simply instructed to allow their mind to wander
during the scan. Resting-state fMRI data were preprocessed in SPM12
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). Functional
images were slice-time corrected, co-registered to their anatomical
images, realigned and resliced to 2 × 2 × 2 mm3 isotropic voxels, un-
warped to correct for field inhomogeneity, normalized to the standard
three-dimensional space of the Montreal Neurological Institute (MNI),
and spatially smoothed using a 6 mm isotropic Gaussian kernel. Outliers
from motion and global signal intensity were identified using the ART
toolbox https://www.nitrc.org/projects/artifact_detect/. Images with
movement from a preceding image exceeding 0.5 mm or a global mean
intensity>3 standard deviations were regressed out of the first level
general linear models.
2.4.3. Diffusion tensor imaging (DTI)
DTI scans were acquired using a Siemens Tim Trio 3 T scanner
(Erlangen, Germany) at McLean Hospital Imaging Center. Diffusion-
weighted imaging (DWI) data were acquired along 72 directions with a
b-value of 1000 s/mm2 and following parameters: voxel
size = 1.75 × 1.75 × 3.5 mm3, TR = 6340 ms, TE = 99 ms, flip
angle = 90° and 40 axial slices with thickness = 3.5 mm, encom-
passing the whole brain. A set of 8 images with no diffusion weighting
(b0 images) was also acquired. Using dcm2nii toolbox (part of MRIcron
(Rorden et al., 2007)), we converted DWI data from DICOM into NIFTI
format. A b-value and b-vector file was generated during this step. The
raw data were imported into the DSI Studio (http://dsi-studio.
labsolver.org) and converted into SRC format. Each SRC file under-
went standard eddy current and subject movement correction, followed
by a thorough examination using quality control (QC) procedure to
ensure the quality and integrity of data. Neighboring DWI correlation
(NDC) values for the current data set were>0.95. No outlier in NDC
values (> 3 median absolute deviation) was identified.
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2.5. Data analysis
Data analysis followed a sequential process. First sleep and perfor-
mance measures were compared between pre- and post-treatment.
Second, we compared gray matter volume (GMV) in the brain between
pre- and post-treatment using voxel-based morphometry (VBM). As
discussed in detail below, two separate clusters within the left and right
thalamus demonstrated significant increases in volume following
treatment with BLUE light. Third, the resulting significant GMV clusters
were used as seed regions of interest (ROIs) in a subsequent resting state
functional connectivity (rsFC) analysis. Significant functional con-
nectivity values between the seed ROIs and associated cortical clusters
(ROIs) were extracted for further analysis. Fourth, the functional con-
nectivity data were also analyzed using Granger causality (GC) analysis
to determine the directional nature of the connectivity patterns. Areas
which were not found to be structurally connected were not analyzed
using GC. Lastly, the seed and target ROIs resulting from the rsFC
analysis were implemented as endpoint regions in a fiber tractography
analysis using the diffusion tensor imaging scan data. Once fiber tracts
were defined for each individual, standard DTI metrics of fiber pathway
integrity were extracted and compared between pre-and post-treatment
for each light condition. The resulting metrics from each region were
extracted for further analysis with relevant behavioral outcome metrics.
2.5.1. Actigraphic sleep analysis
Actigraphic data were downloaded and then processed and scored
in Actiware® 6 (Philips Respironics) according to standardized proce-
dures. For the present analysis, we averaged the minutes of sleep ob-
tained for each overnight sleep opportunity for the first six nights of the
baseline week (i.e., between Visit 1 and 2) and the final six nights
preceding the post-treatment visit (Visit 3). For each participant, sleep
onset time, wake time, sleep duration, sleep efficiency, and wake after
sleep onset (WASO) was calculated. A 2 between (light colour: blue vs
amber) x 2 within (time: baseline vs post-treatment) mixed analysis of
variance (ANOVA) was conducted on each of these variables separately.
For all behavioral analyses, we controlled for a set of variables likely to
affect sleep, including concussion severity (RPCSQ and occurrence of
loss of consciousness (LOC) from the most recent concussion), depres-
sion (BDI), and participant age. As appropriate, for select sleep mea-
sures, change metrics were also examined as dichotomous outcome
variables (i.e., improvement vs. no-improvement) to allow determina-
tion of odds ratios (OR).
2.5.2. Cognitive/behavioral performance analysis
To assess the effects of light treatment group on cognitive and be-
havioral measures, data from self-report questionnaires (e.g., ESS) and
cognitive metrics (e.g., TOL) were computed as a change from baseline.
These change scores were then compared using one-way ANCOVA,
controlling for RPCSQ, LOC, BDI, and age. As appropriate, for select
behavioral measures, change metrics were also examined as dichot-
omous outcome variables (i.e., improvement vs. no-improvement) to
allow determination of odds ratios (OR).
2.5.3. GMV statistical analysis
Statistical analyses were conducted in several stages. First, pro-
cessed GMV data from CAT12 were analyzed in SPM12. A 2 between
(blue vs. amber) x 2 within (baseline vs. post-treatment) mixed analysis
of variance (ANOVA) was conducted within SPM12 using the flexible
factorial option, controlling for age, intracranial volume, and the
number of days the light device was used (according to online sleep
logs). Maps were cluster corrected for family-wise error (FWE,
p < .05) at the whole brain level. Resulting clusters were then com-
pared from pre-to post-treatment using paired t-tests in SPM12 for the
BLUE light group, with age, intracranial volume, and the number of
total days in the study during which participants reported using the
light device entered as nuisance covariates. To increase precision,
separate search territories were placed for the left and right thalamus
using the automated anatomic labeling atlas (AAL; (Tzourio-Mazoyer
et al., 2002)). We used a cluster-extent based thresholding, following
the recommended approach suggested by Woo, Krishnan, and Wager
(Woo et al., 2014), applying a primary significance threshold of
p < .001, uncorrected, as the default lower limit. Based on this pri-
mary height threshold, SPM12 provided the critical cluster size for
cluster-extent correction with family-wise error (FWE) maintained at
p < .05 for the search territory. Between group t-tests were conducted
for the BLUE group and resulting significant clusters were used a re-
gions of interest (ROIs) that were then compared for the AMBER group
to constrain for multiple comparisons. Using the Region Extraction Tool
(REX), the mean GMV estimates were extracted for each cluster for the
BLUE and AMBER groups separately and exported to IBM SPSS Statis-
tics 25 for further analyses.
We were interested in the associations between the change metrics
for each neuroimaging parameter and several cognitive/behavioral
outcome variables. Here, the volumetric change values for each cluster
were extracted for each individual for correlation with cognitive/be-
havioral measures of interest. A hierarchical multiple regression pro-
cedure was employed, including covariates for age, intracranial vo-
lume, and the number of days the light was used (as determined from
online sleep logs) in the first block of the analysis, followed by the
specific change values for GMV in the second block. After controlling
for covariates, the partial correlation coefficient calculated between
GMV change and the cognitive/behavioral metrics.
2.5.4. Functional connectivity analysis
A single subject was removed from each group from subsequent
fMRI analyses, as> 20% of their scans were identified as outliers. An
independent samples t-test indicated no significant difference between
groups in the number of outliers identified and incorporated into sub-
sequent first level models at baseline (p = .09) and post-treatment
(p = .54).
Here, we used the two GMV clusters identified in the previous
analysis (i.e., left pulvinar (LPul) and right pulvinar (RPul)) as seed
regions for resting state functional connectivity (rsFC) analyses.
Functional connectivity analyses were performed with a seed-to-voxel
driven approach within the CONN toolbox V17.f (Whitfield-Gabrieli
and Nieto-Castanon, 2012). Preprocessed structural and resting state
data had physiological and other noise sources identified as nuisance
covariates using a component-based noise correction method
(CompCor). The first acquisition image, images identified as outliers,
nuisance covariates, as well as white matter and cerebrospinal fluid
masks, were regressed out of the first level general linear models. The
BOLD time series was then band pass filtered at 0.01–0.1 Hz. Individual
subject seed-to-voxel whole-brain connectivity maps were created for
the LPul and RPul seeds with the mean time series from each seed used
as a predictor in a multiple regression General Linear Model (GLM). The
resulting individual bivariate correlation coefficients were Fisher
transformed into Z-scores for subsequent second level analyses.
2.5.4.1. Seed-to-voxel analysis. Two analyses were performed at the
second level to create statistical parametric maps (SPMs) representing
associated changes in functional connectivity for each seed region.
Repeated measures two-way ANCOVAs were used to investigate the
main effect on functional connectivity associated with BLT, with mean-
centered age and mean-centered days light used as covariates within
the models. SPMs for each seed were defined with a cluster-forming
threshold (voxel-level uncorrected P < .001) and a cluster-level extent
threshold (Family Wise Error (FWE) corrected P < .05), using a
positive contrast, to identify clusters of voxels associated with
significant increases in connectivity to the seed region. No clusters
were identified using the RPul seed, and three clusters were identified
using the LPul seed. A mask was created for each cluster identified
containing voxels that correlated with the LPul seed, in order to further
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investigate Regions of Interest (ROIs) that contained voxels associated
with significant change for the treatment group.
2.5.4.2. Seed-to-ROI analysis. To determine the extent of connectivity
change observed for either treatment group, the BOLD time-series was
extracted from each cluster identified in the seed-to-voxel analyses.
Seed-to-ROI within group connectivity analyses were performed using
paired t-tests with the identified ROIs (i.e. Left Parietal Cortex: LParC,
Left Agranular Frontal Area: LAFA, and the Right Parietal Cortex:
RParC), and the LPul seed. Mean-centered age and mean-centered days
light used were included in the models as covariates and results were
corrected for multiple comparisons (p < .05, seed-level FDR-
correction).
The functional connectivity values for each connection were ex-
tracted for each individual for further correlation with cognitive/be-
havioral measures of interest. We applied hierarchical multiple re-
gression procedures, including covariates for age and the number of
days the light was used (as determined from online sleep logs) in the
first block of the analysis, followed by the specific functional con-
nectivity parameter of interest in the second block. After controlling for
covariates, the partial correlation was determined for the parameters of
interest.
2.6. Directed functional connectivity (DFC) analysis: Granger causality
(GC)
Raw time-series data were band pass filtered using the Butterworth
filter design using higher cutoff frequency of 0.0028 Hz (f1) and a lower
cutoff frequency of 0.1 Hz (f2). Higher cutoff frequency was determined
from time-series length (n = 180 time-points) and repetition time
(TR = 2 s) as following:
= =f
n TR
1 0.0028Hz1
The lower cutoff frequency of 0.1 Hz was selected because low
frequency (< 0.1 Hz) BOLD fluctuations often show strong correlations
at rest (Cordes et al., 2001). The ensemble means from the time-series
for each node were removed to make the zero-mean process for GC
analysis. Moreover, these steps helped to remove slow trends and
physiological noise associated with respiratory and cardiac activities.
A spectral interdependency method (Dhamala, 2013) was used to
estimate the DFC between ROIs by quantifying the inter-relationships
between their corresponding oscillatory mechanisms as a function of
frequency (f) of oscillations. Directional influences between two re-
gions, say a and b, are estimated from a spectral density matrix (S).
Matrix S is constructed parametrically from the time-series of systems a
and b using autoregressive (AR) modeling as following:
=GC S f
H f H f
ln ( )
( ) ( )
a b
bb
aa aa aa
=GC S f
H f H f
ln ( )
( ) ( )
b a
aa
bb bb bb
Here, = +H H Haa aa abab
aa
and = +H H Hbb bb baab
bb
represent new
transfer function matrices for a and b respectively in terms of noise
covariance matrix, ∑ and transfer function matrix H. Here, * denotes
matrix adjoint. Mathematical details of these estimations are docu-
mented previously (Dhamala, 2013).
GC measures can be computed by either parametric or non-para-
metric methods (Dhamala et al., 2008a; Dhamala et al., 2008b). In this
study, we used the parametric approach. The optimal model order for
parametric approach was calculated by comparing power spectra from
the parametric and non-parametric approaches (Dhamala et al., 2008a).
Different model orders from 1 to 10 were tested, and the model order,
which yielded the lowest power difference, was selected. The threshold
level for statistically significant directed functional connection was
estimated from surrogated data by using permutation test (n = 1000)
and a gamma function under a null hypothesis of no interdependence at
the significance level of p < 10−4 (Blair and Karniski, 1993; Brovelli
et al., 2004) (p = 10−4/16, corrected for multiple comparisons). Pre-
viously, the GC technique has been shown to have consistent results
with the dynamic causal modeling technique, in terms of directional
connectivity from resting-state fMRI data (Bajaj et al., 2016).
For the present analyses, the range of GC metrics was extracted for
each individual and correlated with cognitive/behavioral measures of
interest. Using hierarchical multiple regression procedures, covariates
including age, intracranial volume, and the number of days the light
was used were entered at a first block, followed by the specific GC range
parameter of interest at the second block, and the partial correlation
was determined for the parameters of interest.
2.7. Anatomical connectivity analysis: DTI
Diffusion MRI connectometry (Yeh et al., 2016) was performed to
compare longitudinal pair-wise scans between pre and post-treatment
conditions for both amber-light treatment (ALT) and blue-light treat-
ment (BLT) groups. The connectometry approach, which is im-
plemented in DSI Studio, uses a permutation test to perform the long-
itudinal pairwise comparison between white-matter pathways. Tracts,
which showed significant longitudinal differences along axonal fiber
directions, were identified using a deterministic tractography algorithm
(Yeh et al., 2013). Group averages of local connectome were quantified
in terms of their differences in density and diffusivity measurements of
water diffusion, including fractional anisotropy (FA) as well as isotropic
(ISO) diffusion. Here, FA is one of the most common diffusivity mea-
sures, which is defined for each voxel and represents how fast water
diffuses, whereas ISO is a density measure and represents how much
water diffuses in an isotropic fashion. Both FA and ISO components
were estimated using the Q-space diffeormophic reconstruction (QSDR)
(Yeh and Tseng, 2011) approach implemented in DSI Studio. QSDR is a
model-free approach, which calculates the distribution of water diffu-
sion using a high-resolution standard brain atlas constructed from 90-
diffusion spectrum imaging datasets in the ICBM-152 space. Automated
registration to standard template space was used for each subject. All
the regions of interest (ROIs) were transformed into MNI space in order
to perform diffusion MRI connectometry in QSDR-space. A seed-count
of 5000 sub-voxels for each region (LPul, LParC and LAFA) was used for
connectometry analysis. All the ROIs were dilated to 3 mm to extend to
white matter. Tracts with differences in FA and ISO diffusion were
identified for all the connections, which showed significant involve-
ment in functional connectivity analysis i.e., between LPul and LParC
and between LPul and LAFA. To limit the tracts between LPul and
LAFA, LPul was used as a seed region as well as an end region and LAFA
was used as an end region. A lower T-value threshold of 0.5 was used to
identify tracts which were more sensitive to light treatment. Track
pruning was conducted using 10 iterations, and tract length threshold
was 30 voxels. A total of 10,000 permutations and false discovery rate
(FDR) of 0.05 were used to obtain the null distribution of the tract
length. Subject-wise differences for the tracts that showed differences
(at FDR between 0 and 0.2) in either FA or ISO diffusion measures were
extracted for further correlation analysis with behavioral parameters.
Using hierarchical multiple regression procedures, covariates including
age, intracranial volume, and the number of days the light was used (as
determined from online sleep logs) were entered at a first block, fol-
lowed by the specific ISO diffusion parameter of interest at the second
block, and the partial correlation was determined for the parameters of
interest.
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3. Results
3.1. Baseline metrics
As evident in Table 1, light condition groups were similar on key
variables at baseline, including sex, age, years of education, number of
previous concussions, months since injury, concussion severity, de-
pression, functional outcomes of sleep, chronotype, and days of com-
pliance with light treatment (determined from daily time-stamped
website diary completion). Half of participants (n = 16) reported only
one concussion, while half reported more than one lifetime concussion
(range 1 to 7 total). Of those reporting more than one concussion, the
modal response (i.e., endorsed by 5 participants) was 2 head injuries.
3.2. Actigraphic sleep
BLUE light produced a significant phase advance in sleep onset and
offset times relative to AMBER light. After accounting for covariates
(baseline concussion symptoms, loss of consciousness (LOC) from the
most recent concussion, depression (BDI), age), there was a significant
light-condition x time interaction, F(1, 21) = 6.16, p = .022 (Fig. 3a).
Over the course of treatment, planned comparisons showed that parti-
cipants in the BLUE condition were phase advanced in sleep onset
times, generally falling asleep 57.5 min earlier in the final week of the
study compared to baseline (p = .004), while those in the AMBER
condition fell asleep 13.8 min later compared to baseline (p = .508).
Overall, 80% of participants in the BLUE condition showed some evi-
dence of earlier sleep onset, while 58.3% of those in the AMBER group
did (χ2 = 1.50, p = .221). After accounting for covariates (described
above), the odds ratio (OR) for showing any phase advancement with
BLUE light compared to AMBER was 13.04 (95% CI: 0.84 to 202.52;
p= .066. Further, planned comparisons showed that participants in the
BLUE condition were awakening 55.9 min earlier by the final week of
treatment compared to baseline (p = .037), whereas the AMBER con-
dition was awakening only 16.1 min earlier after treatment (p = .576;
see Fig. 3b). Overall, 66.7% of participants in the BLUE condition
showed some evidence of earlier wake times, while 50% of those in the
AMBER group did (χ2 = 0.77, p= .38). After accounting for covariates
(described above), the odds ratio (OR) for showing any phase ad-
vancement with BLUE light compared to AMBER was 3.68 (95% CI:
0.55 to 24.74; p= .18. There were no significant changes in mean total
sleep time (TST) per night between pre- and post-treatment assess-
ments, regardless of light-condition (all p-values> .05; see Fig. 3c).
There was a nonsignificant trending difference between light-condition
groups in the extent of circadian phase shift (CPS; i.e., taking the
midpoint between sleep onset and offset for each participant) from
baseline, F(1, 21) = 4.18, p= .054 (see Fig. 3d), such that those in the
BLUE light condition showed an average circadian phase advance in the
midpoint of the sleep period of 60.1 min, whereas those in the AMBER
light condition shifted earlier by only 1.9 min on average. Overall,
while 73.3% of participants who received BLUE light showed at least
some evidence of phase advancement, 58.3% of those in the AMBER
group also showed at least some phase advancement (χ2 = 0.675,
p = .411). After accounting for covariates (described above), the odds
ratio (OR) for showing any phase advancement with BLUE light com-
pared to AMBER was 7.34 (95% CI: 0.59 to 90.71; p = .12.
3.3. Sleepiness and subjective sleep need
Relative to placebo, the BLUE light intervention led to reduced ty-
pical daytime sleepiness F(1,26) = 5.49, p = .027 (see Fig. 4a).
Moreover, we found that 87.5% of the participants in the BLUE light
condition showed reduced sleepiness scores from pre- to post-treat-
ment, whereas only 37.5% of those in the AMBER placebo condition
showed any measurable reduction in sleepiness over the same time
frame ((χ2 = 8.53, p = .003; see Fig. 4b). After controlling for cov-
ariates (described above), the odds ratio (OR) for showing any im-
provement in daytime sleepiness was 25.63 (95% CI: 2.76 to 237.84;
p = .004; Nagelkerke R2 = 0.446). We also found that the number of
hours necessary to subjectively “feel best” was reduced for the BLUE
light condition (M = −1.51, SE = 0.47) relative to AMBER
(M = 0.043, SE = 0.47), F(1,26) = 4.99, p = .034 (see Fig. 4c).
Fig. 3. Effects of light treatment on actigraphic sleep
measures. (a) Blue light shifted sleep onset time by
57.5 min earlier by the end of treatment, versus no
change for the amber group. (b) Blue light shifted
wake time by 55.9 min earlier by the end of treat-
ment, but there was no difference for amber light. (c)
There was no significant effect of light condition for
change in total sleep time (TST) from pre- to post-
treatment. (d) A comparison of the midpoint of sleep
onset and wake time for each light group showed
that blue light was associated with a non-significant
trend toward a circadian phase advancement in the
sleep period of 60.1 min by the end of treatment.
Error bars represent 1 SE. (For interpretation of the
references to colour in this figure legend, the reader
is referred to the web version of this article.)
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3.4. MSLT
As an objective measure of daytime sleepiness/alertness, partici-
pants completed a modified version of the MSLT over three time points
at baseline and post-treatment. Notably, it was only the second MSLT,
occurring in the early afternoon (1:50 p.m.) proximal the “post-lunch
dip” (Monk, 2005), that showed a significant light-condition x time
interaction, F(1, 26) = 5.26, p = .030 (see Fig. 4d–f), suggesting that
from pre- to post-treatment, participants in the BLUE light condition
showed increased latency to fall asleep during the mid-day (i.e., were
more alert). There were no significant light-condition x time interac-
tions for the early morning or late afternoon MSLT sessions.
3.5. Cognitive/behavioral performance
Participants completed multiple cognitive and behavioral tasks at
baseline and after 6-weeks of intervention with either the BLUE or
AMBER light.
3.5.1. Psychomotor vigilance
At the first psychomotor vigilance test (PVT), which occurred in the
late morning (11:30 a.m.), there was no significant light-condition x
time interaction, F(1, 22) = 0.062, p = .805 (see Fig. 4g), with both
groups slowing in reaction time (RT) during the post-treatment session
relative to baseline, and no group differences. By the second PVT, in the
early afternoon (1:25 p.m.), near the “post-lunch dip”, there was a non-
significant light-condition x time interaction, F(1, 22) = 2.985,
p = .098 (see Fig. 4h), with post-hoc tests indicating that from pre- to
post-treatment, participants in the AMBER light condition showed sig-
nificant slowing of RT (p < .005), while those participants in the BLUE
light condition sustained RT from pre- to post-treatment. Finally, by
late afternoon (3:25 p.m.), the light-condition x time interaction re-
mained non-significant F(1, 22) = 0.797, p = .382 (see Fig. 4i).
Fig. 4. Effects of light treatment on behavioral variables. (a) Blue light led to a significant reduction in daytime sleepiness scores on the Epworth Sleepiness Scale
(ESS), with (b) a significantly greater percentage of blue light participants showing some improvement in daytime sleepiness relative to amber participants. (c) Blue
light was associated with a significant reduction in the number of nightly hours of sleep that participants reported needing to feel their best, relative to the amber
group. (d-f) Sleep onset latency on the multiple sleep latency test (MSLT) was unaffected by light condition in the late morning (11:50 a.m.) or late afternoon
(3:50 p.m.), but showed a significant interaction for the early afternoon “post-lunch dip” period. Similarly, (g-i) psychomotor vigilance test reaction time did not
differ between groups during the late morning (11:30 a.m.) or late afternoon (3:25 p.m.), but was affected by blue light only in the early afternoon. Although there
was (j) no effect of light condition on the total number of moves from the Tower of London (TOL) test, (k) blue light was associated with a significant improvement in
average bead movement times relative to amber light, and (l) when speed and accuracy were combined as a metric of “throughput”, blue light was associated with
significantly more correct moves per minute than the amber placebo group. (*p < .05), **p < .01, ***p < .005). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Voxel-based morphometry results for blue versus amber light treatment. Results of a whole brain voxel-based morphometry (VBM) analysis comparing
baseline and post-treatment changes for those receiving the blue light condition. (a) The figure shows the sagittal (left) coronal (middle) and axial (right) or-
ientations. This analysis showed significant increases in gray matter volume (GMV) within the left (567 voxels; MNI: x =−3, y =−22, z = 3) and right (119 voxels;
MNI: x = 3, y = −22, z = 3) posterior thalamic volume for those receiving the BLUE light intervention (pFWE < 0.05). (b) Extracted volumes from each of these
clusters are plotted in the figures for visualization for the left and the right thalamic regions for the BLUE and AMBER groups separately. The location of the left and
right thalami are represented by the red wire mesh areas of the figure. It is clear that BLUE light was associated with significant increases in the volume of both the
left and right posterior regions, but this was not evident for the same regions in the AMBER group. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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3.5.2. Neuropsychological performance
Contrary to predictions, light condition had no significant effect on
mean performances on a brief neurocognitive performance battery
(RBANS), which included immediate Memory, Visuospatial/
Constructional, Language, Attention, Delayed Memory, and RBANS
Total Score.
3.5.3. Executive functioning
On the Tower of London (TOL), a classic executive function plan-
ning task, the light condition did not affect the number of moves re-
quired to solve the puzzles between pre- and post-treatment, F
(1,26) = 0.08, p = .79 (see Fig. 4j). However, the light-condition did
affect the time taken to solve the puzzles, F(1,26) = 7.45, p = .01 (see
Fig. 4k). On average, participants who underwent the BLUE wavelength
light condition were 1280 (SE = 234) ms faster in completing each
move following treatment, while those in the AMBER placebo condition
improved by only 325 (SE = 234) ms per move. When speed and ac-
curacy were combined as a measure of “throughput,” there was a sig-
nificant effect of light condition, F(1,26) = 4.26, p= .049. As shown in
Fig. 4l, participants in the BLUE light condition showed an increase in
the number of correct bead placements of 4.23 (SE = 0.83) per minute,
whereas those in the AMBER condition increased by only 1.73
(SE = 0.83) per minute after treatment. Overall, most participants
showed at least some improvement in TOL performance, regardless of
condition, with 93.8% of participants in the BLUE group and 81.3% of
participants in the AMBER group showing greater throughput after 6-
weeks (χ2 = 1.143, p = .285). After accounting for covariates (de-
scribed above), the odds ratio (OR) for showing any improvement in
throughput with BLUE light compared to AMBER was 6.50 (95% CI:
0.41 to 102.15; p = .183.
3.6. Gray matter volume (GMV)
To examine morphometric volume changes in the brain, the ana-
tomical brain images obtained during the MRI scan were analyzed in
SPM12 with a 2 between (BLUE vs. AMBER) x 2 within (baseline vs.
post-treatment) mixed analysis of covariance (ANCOVA), controlling
for age, intracranial volume, and the number of days the light device
was used. The ANCOVA yielded a large bilateral cluster (807 voxels,
pFWE < 0.05; MNI: x = 0, y = −21, z = 3) reflecting a significant
light dependent change in volume from pre- to post-treatment. This
region was constrained to the pulvinar regions of the left (LPul) and
right (RPul) thalamus (Fig. 5a). Given the significant interaction, we
examined the effects of each light condition individually. As shown in
Fig. 5b, a pre- to post-treatment t-test for those receiving the BLUE light
condition showed that this effect was driven primarily by an increase in
thalamic GMV (bilateral) (pFWE < 0.05), but this was not evident for
the AMBER light condition.
Multiple regression was used to determine the partial correlations
between changes in pulvinar volume and performance metrics. As
shown in Fig. 6a–c, after controlling for age, intracranial volume, and
the number of days of light device use, greater volume increases in the
pulvinar region of the left thalamus were associated with faster bead
pickup time, faster total move time on the TOL, and with a slight in-
crease in subjective ratings of sleepiness at post-treatment, measured
using the SSS. Right thalamic volume changes were not associated with
any measured changes in cognitive/behavioral scores.
3.7. Functional connectivity
Building on the GMV findings above, we used the two previously
identified thalamic clusters (i.e., LPul and RPul) as seed regions in a
seed-to-voxel and seed-to-ROI resting state functional connectivity
(rsFC) analysis. Repeated measures two-way ANCOVAs were used to
investigate the main effect of light-condition on rsFC from pre- to post-
treatment.
3.7.1. Seed-to-voxel analysis
Relative to the AMBER light condition, individuals in the BLUE light
condition showed increased rsFC from pre- to post-treatment between
the LPul seed and voxels comprising three separate areas (Fig. 7a),
including a region in the left parietal cortex (LParC; β = 0.34,
p = .001), the right parietal cortex (RParC; β = 0.31, p < .001), and
left agranular frontal area (LAFA; β = 0.34, p< .001). In contrast, the
RPul seed region did not show any significant increase in connectivity
with other voxel clusters in the brain.
3.7.2. Seed-to-ROI analysis
Within each light-condition, we examined the ROI-to-ROI con-
nectivity. Consistent with the seed-to-voxel analysis, mean rsFC was
significantly increased for the BLUE light condition over the course of
treatment between the LPul and the three ROIs, including the LParC, t
(25) = 2.38, p = .03, RParC, t(25) = 2.26, p = .03, and LAFA, t
(25) = 2.33, p = .03). For the AMBER light condition, significant de-
creases in connectivity over the course of treatment between the LPul
and ROIs were found for all three ROIs, including the LParC, t
(25) =−3.58, p = .002, RParC, t(25) =−3.65, p= .001, and LAFA, t
(25) = −4.16, p < .001 (Fig. 7b).
As shown in Fig. 6d–g, after controlling for standard covariates,
increased rsFC between LPul and LParC ROIs from pre- to post-treat-
ment was associated with a significant reduction in daytime sleepiness
on the ESS (r (23) = −0.50, p = .011), increased scores on RBANS
Language (r (23) = 0.418, p= .038), TOL average bead pickup time (r
(23) = −0.439, p = .028), and TOL Average total move time (r
(23) = −0.411, p = .041). Similarly, increased rsFC between the LPul
and RParC was also associated with faster bead pickup time on the TOL
(r (23) = −0.425, p = .034; Fig. 6h).
3.8. Granger causality (GC)
To determine if the rsFC connectivity change was “bottom-up” (i.e.,
increased thalamocortical connectivity) or “top-down” (i.e., increased
corticothalamic connectivity), we next employed GC to determine the
directional influence between the previously identified areas of interest.
The previous analysis revealed that FC was only evident for the left
pulvinar connections (i.e., LPul—LParC, LPul—LAFA, and
LPul—RParC). However, we did not find structural connectivity be-
tween LPul and RParC for any subject/condition; therefore only four
connections (C1: LPul to LParC, C2: LParC to LPul, C3: LPul to LAFA,
and C4: LAFA to LPul) were further interrogated using GC.
GC-frequency spectra for all four directional connections (C1, C2,
C3, and C4) were computed. The estimated threshold level of GC
strength used to identify significant connections was 0.0142 at
p < 10−4 (permutation method; corrected for multiple comparisons).
In Fig. 7c–f, it is evident that GC-frequency spectra for all four con-
nections and for all four conditions (AMBER: APre-T (Amber-light pre-
treatment), APost-T (Amber-light post-treatment); BLUE: BPre-T (Blue-
light pre-treatment) and BPost-T (Blue-light post-treatment)) had peaks
at frequency < 0.1 Hz, and showing the connectivity patterns for
APost-T (Fig. 7d) and BPost-T (Fig. 7f). Within the AMBER group, we
found that the C1 connection exceeded threshold only at baseline
(APre-T), but that connection did not exceed the threshold at APost-T
(Fig. 7c). By contrast, in the BLUE group, this same connection did not
reach the threshold at BPre-T, but exceeded the threshold at BPost-T
(Fig. 7e–f). Connection C2 did not exceed the threshold for either BLUE
or AMBER conditions (Fig. 7c and e). In addition, two connections (C3
and C4) exceeded the threshold for connectivity at pre- and post-
treatment for both the AMBER and BLUE groups, suggesting that these
connections were not meaningfully affected by light condition. In sum,
the findings suggest that connection C1 (LPul to LParC) was sig-
nificantly affected by light condition, showing a decrease in directed
bottom-up connectivity in the AMBER group and an increase in this
bottom-up connectivity within the BLUE group. Other connections
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either remained below the threshold or were essentially unchanged by
light condition.
As in the previous analyses, we also examined the cognitive/beha-
vioral correlates associated with changes in causal flow. As shown in
Fig. 6i–k, after controlling for age, intracranial volume, and the number
of days of light device use, increased causal influence of LPul on LParC
from pre- to post-treatment was not significantly associated with
change in circadian phase (r (19) = 0.387, p = .083), but was asso-
ciated with a significant reduction in typical daytime sleepiness on the
ESS (r (23) = −0.427, p = .033), and a significant reduction in con-
cussion severity scores on the ANAM (r (23) = −0.409, p = .042).
3.9. Anatomical connectivity
We next examined whether the connectivity changes reported above
would be associated with corresponding changes within axonal tracts
connecting the identified regions.
We found that there were no tracts with significant differences be-
tween pre- and post-treatment for fractional anisotropy (FA)
(FDR > 0.05) in either AMBER or BLUE light conditions (Fig. 8a).
However, we found tracts connecting LPul and LParC with a significant
reduction in isotropic diffusion (ISO) (a measure of white matter dis-
integrity) following treatment for the BLUE (Fig. 8b) (FDR < 0.05),
but not for the AMBER light condition (FDR > 0.05). Furthermore, we
found that tracts connecting LPul and LAFA showing reduced ISO dif-
fusion following treatment for the BLUE light condition at a less strin-
gent threshold (FDR = 0.11) (Fig. 8b) and a significant increase in ISO
following treatment for AMBER light condition (FDR < 0.05) (Fig. 8c).
We examined the cognitive/behavioral correlates of changes in ISO
diffusion within specific white matter tracts discussed above. For the
BLUE light condition, subject-wise differences for the tracts connecting
LPul and LParC, and LPul and LAFA, were extracted. For the AMBER
light condition, subject-wise differences for the tracts connecting LPul
and LAFA were extracted. As shown in Fig. 6l–o, only changes in
RBANS measures showed significant associations with changes in white
matter integrity. Specifically, after controlling for age, intracranial
volume, and the number of days the light device was used, decreases in
ISO diffusion from pre- to post-treatment for the BLUE light condition
were associated with improved visual construction (RBANS VC) per-
formance (r (9) = −0.714, p = .014), improved delayed memory
(RBANS DM) performance (r (9) = −0.755, p = .007), and improved
total neuropsychological (RBANS Total) performance (r (9) = −0.607,
p = .048). For the sample as a whole, decreases in ISO diffusion be-
tween LPul and LAFA were associated with improved delayed memory
(RBANS DM) performance (r (23) = −0.460, p = .021), and a trend
toward greater total neuropsychological (RBANS Total) performance (r
(23) = −0.386, p = .057).
4. Discussion
During a 6-week randomized placebo-controlled trial of daily light
exposure, we found that 30-min of morning blue-wavelength light was
more effective than amber-wavelength placebo light at shifting sleep-
wake periods, reducing subjective and objective sleepiness, and
improving cognitive performance among participants recovering from
mTBI. Moreover, compared to amber light, the blue light intervention
was associated with increases in gray matter volume within the pos-
terior thalamus and greater structural and functional thalamocortical
connectivity, as well as multiple associations between improvements in
cognitive performance and the observed physiological changes. These
findings are consistent with the hypothesized role of morning blue-
wavelength light in phase advancing the circadian rhythm of sleep and
alertness, and the postulated role of sleep in accelerating neural repair
processes. Together, these findings point to the ipRGC-SCN-mediated
circadian system as a critical contributor to brain repair processes and
suggest a potential target mechanism for intervention to facilitate re-
covery following brain injury.
Our findings are consistent with well-established evidence that blue
light exposure affects the timing of sleep-wake cycles through stimu-
lation of the retinohypothalamic system (Geerdink et al., 2016), as we
found that the BLUE light condition showed a trend toward phase-ad-
vancement of the midpoint of participants' sleep periods by just over
one hour by the end of treatment, with no meaningful change observed
for the AMBER light condition. Notably, this alteration in sleep timing
was not associated with a measurable change in total sleep time based
on actigraphy. While light treatment has shown robust effects for
shifting sleep timing (Geerdink et al., 2016; Rosa et al., 2018; Tahkamo
et al., 2018), prior research demonstrates mixed outcomes in terms of
modifying total sleep time (TST) or subjective perception of time spent
asleep (Figueiro et al., 2014; Richardson et al., 2018; Saxvig et al.,
2014; Wu et al., 2018). It should be borne in mind, however, that our
primary measure of TST was based entirely on wrist-actigraphy, which
has a satisfactory accuracy level (> 80%) (Marino et al., 2013), but
may not be sensitive enough to detect the subtler effects of light
treatment on sleep architecture.
Recent work demonstrates that daily morning blue light therapy
improves subjective fatigue and daytime sleepiness in patients with TBI
(Sinclair et al., 2014). Our results extend these earlier findings, as our
BLUE light condition led to a significant decline in subjective daytime
sleepiness and a reduction in self-perceived sleep requirement relative
to the AMBER placebo condition. Thus, even though BLUE light did not
lead to an increase in total sleep time after treatment, participants
treated with BLUE light reported a reduced tendency to “doze” off
throughout the day, as well as a decrease in the total time asleep ne-
cessary to feel their best. Moreover, BLUE light use was also associated
with objectively greater daytime alertness, as evidenced by extended
latencies to fall asleep during the early afternoon post-lunch dip,
compared to the placebo condition, when measured using poly-
somnography. The blue-wavelength light intervention was also asso-
ciated with sustained psychomotor vigilance performance in the early
afternoon. Thus, the treatment is associated with improvements in both
subjective and objective daytime alertness for individuals recovering
from mTBI during times when drowsiness is particularly likely to occur.
When directly comparing the groups on neurocognitive perfor-
mance, we found a clear superiority in blue-wavelength treatment
compared to a placebo light treatment on performance during the TOL,
a classic test of visual planning and sequencing ability. Relative to
AMBER light, daily exposure to BLUE light in the morning was
Fig. 6. Association of changes in behavioral measures with changes in voxel-based morphometry, directed connectivity strength, and isotropic diffusion (ISO).
Greater increases in the volume of the left pulvinar region of the thalamus was associated with (a) faster pickup speed, (b) a trend toward faster total move time on
the Tower of London (TOL), and (c) slight increases in subjective sleepiness on the Stanford Sleepiness Scale (SSS). Changes in functional connectivity strength from
pre- to post-treatment for the Left Pulvinar (LPul) and Left Parietal Cortex (LParC) were associated with (d) decreases in daytime sleepiness on the Epworth Sleepiness
Scale (ESS), (e) improvements in language processing on the Repeatable Battery for Neuropsychological Assessment (RBANS), (f) faster average bead pickup time on
the TOL, (g) faster total move time on the TOL. Similarly, increased functional connectivity between the LPul and Right Parietal Cortex (RParC) was associated with
(h) faster total move time on the TOL. We found a significant positive association between changes in directed connectivity strength (LPul to LParC) and (i) changes
in circadian shifts, and significant negative associations with (j) changes in daytime sleepiness, and (k) scores on the concussion severity scale. We also found a
significant negative association between changes in ISO for fibers connecting LPul and LParC and (l) changes in delayed memory scores, as well as (m) total scores on
RBANS battery. ISO for fibers connecting LPul and LAFA also showed a significant negative association with (n) changes in delayed memory scores and (o) total
scores on RBANS battery.
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Fig. 7. Functional Connectivity (FC) and Granger causality measures. (a) The extracted volumes from the VBM analysis were used to investigate the main effect on FC
associated with the observed structural changes in the left thalamic (LPul) and right thalamic (RPul) regions. Individual subject seed-to-voxel whole brain con-
nectivity maps identified three clusters of voxels associated with significant increases in connectivity to the LPul. The extracted clusters (i.e. Left Parietal Cortex:
LParC, Left Agranular Frontal Area: LAFA, and the Right Parietal Cortex: RParC), are plotted in the figures for visualization with the strength of the correlation
represented by the colour of the line. (b) The resting-state correlations for FC between the LPul and ROIs were extracted as beta weights for each participant and the
correlation is plotted for the BLUE and AMBER groups separately with error bars representing the within-group standard errors. (c-f) Next we show that the peaks
from GC-frequency spectra are at frequency < 0.1 Hz for the directed connectivity from the LPul to LParC (C1), LParC to LPul (C2), LPul to LAFA (C3), and LAFA to
LPul (C4) for both ALT group (c-d) (Pre-treatment: APre-T and Post-treatment: APost-T), and BLT group (e-f) (Pre-treatment: BPre-T and Post-treatment: BPost-T).
Dotted lines represent the threshold value of GC estimated from the permutation test at p £10−4. Overall, GC measures between LPul and LAFA (C3 and C4) for
APost-T (e) and between LPul and LAFA (C3 and C4) as well as from LPul to LParC (C1) for BPost-T (f) showed significant directional influence. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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associated with a significant improvement in the completion speed of
each move. Moreover, participants in the BLUE light condition also
made more correct moves per unit of time, suggesting greater efficiency
in planning and execution when compared to those in the placebo
group. To our knowledge, this is the first study to examine the effects of
daily blue-wavelength light exposure on executive function tasks that
incorporate planning and sequencing ability. Further research will be
necessary to determine the extent and nature of neurocognitive changes
produced by daily exposure to blue light in the morning.
While prior research suggests an association between regular ex-
posure to blue light in the early waking hours and reduced fatigue and
sleepiness in patients with TBI (Sinclair et al., 2014), the underlying
neurobiological mechanisms contributing to these effects have re-
mained unclear. Recently, Clark and colleagues demonstrated that fa-
tigue following mTBI was explicitly associated with reduced thalamic
volume (Clark et al., 2018). We found that the BLUE light intervention
was associated with a significant increase in GMV of the mediodorsal
and pulvinar regions of the thalamus bilaterally compared to the
AMBER light condition. Some studies suggest that the thalamus is
particularly vulnerable to the disruptive effects of mTBI (Bolzenius
et al., 2018; Naess-Schmidt et al., 2017), perhaps due to its centralized
location and extensive anatomical/functional connectivity. Further-
more, increases in mean thalamic volume correlate with the recovery of
cognitive performance in individuals with mTBI (Munivenkatappa
et al., 2016). Sleep loss is associated with decreased thalamic volumes,
suggesting a potential role for sleep in modulating the volume of the
thalamus (Dai et al., 2018; Liu et al., 2014). Our findings suggest that
alterations in circadian rhythms or improvements in sleep secondary to
daily blue light exposure may contribute to the observed structural
changes and associated performance outcomes in this study.
The BLUE light condition was associated with increased functional
connectivity between the left thalamus and cortical regions in the
frontal and parietal cortex, relative to the AMBER condition, and this
change correlated with improvements in daytime sleepiness, language
performance, and executive functioning. This effect is consistent with
prior research showing negative correlations in thalamocortical func-
tional connectivity and fatigue in patients with mTBI (Nordin et al.,
2016). Compared to non-injured controls, patients with mTBI have
decreased functional connectivity between the thalamus and cortical
regions including the dorsal attention network and the frontoparietal
control network (Banks et al., 2016). Moreover, these patterns of dis-
rupted connectivity tend to attenuate throughout recovery, with posi-
tive associations between symptom improvement and increases in
connectivity across these networks (Banks et al., 2016). Our findings
suggest that daily morning exposure to blue-wavelength light may help
facilitate the dynamic relationship between the restoration of con-
nectivity with cognitive and symptom recovery.
Finally, we examined whether the increases in the structural con-
nectivity of axonal pathways secondary to the intervention were asso-
ciated with changes in neurocognitive performance. Prior research in
patients with mTBI demonstrates reductions in white matter anisotropy
between the left thalamus and prefrontal regions in patients with mTBI
(Aoki and Inokuchi, 2016). Our findings suggest that blue light treat-
ment may facilitate the reversal of some of these deficits, as we found
increased structural integrity in axonal tracts connecting the left tha-
lamus to the left prefrontal and left parietal cortex after blue light
treatment. Moreover, the magnitude of increases in the structural in-
tegrity of these pathways correlated with improved neuropsychological
performances, particularly those involving visual construction and de-
layed memory abilities. We propose that the post-treatment decreases
in isotropic diffusion for these tracts may reflect increased myelination,
due to the proliferation of oligodendrocyte precursor cells that have
been previously shown to be enhanced by sleep (Bellesi et al., 2013).
Future research will be necessary to verify this assertion.
Several methodological limitations should be kept in mind. These
include modest capacity to monitor treatment compliance, lack of ex-
perimental control over the direction of gaze when using the light de-
vice, and the use of wrist actigraphy as a proxy for gold-standard
nightly polysomnographic sleep recordings. Further, we also found that
half of the participants reported experiencing more than one lifetime
concussion. Unfortunately, we did not collect data on the time frame
between multiple concussions, which is also a limitation. Finally, the
present analysis only focused on primary outcome variables collected at
baseline and after 6-weeks of treatment. Forthcoming work will explore
actigraphic variables in depth at each week to determine whether sleep
outcomes reach their peak before 6-weeks. With due consideration to
these limitations, we believe that the present findings provide com-
pelling evidence for the role of sleep and circadian systems in brain
repair and suggest that stimulation of the ipRGC-SCN system, via daily
exposure to morning blue-wavelength light, may offer an effective
method for re-entraining the circadian system and facilitating recovery
among individuals with a recent mTBI.
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Fig. 8. Diffusion connectometry analysis for amber-light treatment (ALT) and blue-light treatment (BLT) groups. We found that there were no tracts with significant
differences between pre- and post-treatment conditions for fractional anisotropy (FA) (FDR > 0.05) in either ALT or BLT group (a). However, we found tracts
connecting LPul and LParC with significant reduction in isotropic diffusion (ISO) following treatment for BLT group (b) (FDR < 0.05), but not for ALT group
(FDR > 0.05). Also, there were tracts connecting LPul and LAFA with reduced ISO following treatment for BLT group (FDR = 0.11) (c) and a significant increase in
ISO following treatment for ALT group (FDR < 0.05) (c). Here, identified tracts are colour-coded in transverse (right-left: red), longitudinal (anterior-posterior:
green) and horizontal (foot-head: blue) directions and overlaid on colour-coded FA image. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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